In order to thrive, you need to have all of the tools at your fingertips, and that includes evidence-based therapies that go beyond conventional oncology.
Download our FREE PDF guide filled with evidence-based therapies that you can start today to manage your Lung Cancer. Click the orange button to get your download now.
Over-diagnosis and over-treatment of many cancers is not a question. It is a fact of oncology. DCIS, Melanoma, PCa, and others. After studying the issue since my own cancer diagnosis in early 1994, the conclusion I have come to is that
My guess is that if you are reading this post, you or a loved one has recently been diagnosed with lung cancer by LDCT. So you have to wonder if you are actually facing a lung cancer diagnosis.
In my experience, your choices are the following:
If you determine that you don’t have lung cancer you will be thankful and some of the non-toxic anti-cancer changes to your life may stick. As a result you will probably not be diagnosed with other chronic diseases as a result.
If you do, in fact, have lung cancer, you are “pre-habilitating” yourself. According to research, you will respond better and heal faster by your pre-habilitation.
Please understand that conventional oncology- diagnostic imaging, therapies such as surgery, chemo and radiation, all are pieces of the puzzle. But only pieces. Your job is to learn about the full spectrum of evidence-based lung cancer therapies.
To learn more about the full spectrum of evidence-based therapies, scroll down the page, post a question or a comment and I will reply to you ASAP.
Hang in there,
“Abstract- In low-dose computed tomography (LDCT) screening for lung cancer, all three main conditions for overdiagnosis in cancer screening are present:
The degree of overdiagnosis in cancer screening is most validly estimated in high-quality randomised controlled trials (RCTs), with enough follow-up time after the end of screening to avoid lead-time bias and without contamination of the control group.
Nine RCTs investigating LDCT screening were identified. Two RCTs were excluded because lung cancer incidence after the end of screening was not published. Two other RCTs using active comparators were also excluded. Therefore, five RCTs were included: two trials were at low risk of bias, two of some concern and one at high risk of bias. In a meta-analysis of the two low risk of bias RCTs including 8156 healthy current or former smokers, 49% of the screen-detected cancers were overdiagnosed. There is uncertainty about this substantial degree of overdiagnosis due to unexplained heterogeneity and low precision of the summed estimate across the two trials.
Nine randomised controlled trials (RCTs) on low-dose computed tomography screening were identified; five were included for meta-analysis but only two of those were at low risk of bias.
In a meta-analysis of recent low risk of bias RCTs including 8156 healthy current or former smokers from developed countries, we found that 49% of the screen-detected cancers may be overdiagnosed.
There is uncertainty about the degree of overdiagnosis in lung cancer screening due to unexplained heterogeneity and low precision of the point estimate.
If only high-quality RCTs are included in the meta-analysis, the degree of overdiagnosis is substantial…”
“There was 354 lung cancer deaths among those who received CT scans and 442 among those who got X-rays…”
I will be honest. I read studies all the time that indicate that early screening for cancers cause more harm than they prevent. However low-dose CT scans for long-time, high-risk smokers may be an exception to the rule.
The NYT article linked and excerpted clearly demonstrates a benefit for high-risk smokers who get low-dose CT scans. But there is considerable cost involved. And the cumulative effect of radiation may cause serious long-term health risks. More importantly, lung cancer screening can lead to over-diagnosis. The jury is out for now. But I will watch this issue and report back if I find anything…”
“…Dr. Schabath said they are currently validating their radiomic biomarkers in additional cohorts. “If successful, we will conduct a prospective clinical utility trial,” he explained when asked about research next steps. “If that is successful, we would have enough evidence to consider these radiomic biomarkers in standard-of-care.”
MNT also spoke with Dr. Andrea McKee, radiation oncology, director of the Rescue Lung Rescue Life CT lung screening program at Lahey Hospital and Medical Center and national spokesperson for the American Lung Association, about this study.
She believes this could be a useful tool to help identify those individuals with early-stage screen-detected lung cancer who may require care escalation beyond surgical resection, particularly those who may be appropriate candidates for neoadjuvant chemoimmunotherapy.
However, Dr. McKee disagreed with researchers’ characterization of overdiagnosis in lung cancer screenings in their study. “The mischaracterization of overdiagnosis and false-positive rates in CT lung screening is one of the identified barriers to adoption of screening in the US and abroad,” she explained.
“Until we correct these important screening metric misconceptions, I fear we will continue to observe low screening uptake rates among high-risk individuals.”
For next steps in this research, Dr. McKee said she would like to see this analysis performed controlling for histology and in a current screening population where modern imaging and reporting techniques — those which exclude pulmonary ground glass opacityTrusted Source (GGOs) — are utilized.”